PIPER Surveillance Study

piper study image

INTERCEPT Blood System for Platelets, pathogen reduction system

The INTERCEPT Blood System for platelets received FDA approval in 2014, to reduce the risk of transfusion transmitted infection (TTI), including sepsis, and to potentially reduce the risk of transfusion-associated graft versus host disease (TA-GVHD).

PIPER Surveillance Study is Currently Enrolling

PIPER Phase IV Study Logo

To extend further the safety profile of INTERCEPT platelets, Cerus is executing a post-marketing active surveillance study, or the Phase IV INTERCEPT Platelets Entering Routine use (PIPER) Study. PIPER is a prospective, open-label study designed to evaluate the transfusion of conventional and INTERCEPT treated platelets in hematology/oncology patients, including those undergoing hematopoietic stem cell transplant, who are expected to require one or more platelet component transfusions.

PIPER will evaluate of the frequency of assisted mechanical ventilation required to treat severe pulmonary complications, a common clinical concern in transfusion medicine as it relates to repeated platelet transfusions in patient populations at risk for pulmonary complications, such as hematology/oncology patients.

 

Participating Study Sites

Smilow Cancer Hospital
Yale - New Haven
New Haven, CT

Vanderbilt University Medical Center
Nashville, TN

Strong Memorial Hospital
Rochester, NY

Roswell Park Cancer Institute
Buffalo, NY

St. Louis Children's Hospital
St. Louis, MO

University of Maryland
School of Medicine
Baltimore, MD

East Carolina University
Greenville, NC

Beth Israel Deaconess
Boston, MA

University of Minnesota
Minneapolis, MN

Memorial Sloan Kettering Cancer Center
New York, NY

 

 

 


The PIPER Phase IV surveillance study is currently open and recruiting hospital participants.

For more information, or to become a study site, please contact Cerus Corporation by email at piper@cerus.com or by visiting www.clinicaltrials.gov.